drugset / Trial / NCT04830397

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

NCT04830397

Phase 2 Completed 84 enrolled Qlaris Bio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.

Timeline

Start
2021-03-31
Primary completion
2022-02-17
Completion
2022-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS-101 Unknown 0.5 % Other
Subject QLS-101 Unknown 1 % Other
Subject QLS-101 Unknown 2 % Other
Comparator Timolol Other / unclassified 0.5 % Other